Onyx Pharmaceuticals Inc (ONXX)

[surf1944]

2:40AM Onyx Pharma Phase 3 Trial of investigational compound Regorafenib in metastatic colorectal cancer meets primary endpoint of improving overall survival (ONXX) : Co announces results from a Bayer HealthCare Pharmaceuticals (BAYRY) Phase 3 trial evaluating the investigational compound regorafenib for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significant improvement in overall survival. Onyx recently entered into an agreement with Bayer under which Bayer will pay Onyx a royalty on any future global net sales of regorafenib in oncology. Bayer will continue discussions with health authorities worldwide, including the EMA and FDA regarding next steps in filing for approval of regorafenib in the treatment of mCRC.